全文获取类型
收费全文 | 3221篇 |
免费 | 224篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 82篇 |
妇产科学 | 44篇 |
基础医学 | 542篇 |
口腔科学 | 21篇 |
临床医学 | 389篇 |
内科学 | 639篇 |
皮肤病学 | 84篇 |
神经病学 | 388篇 |
特种医学 | 90篇 |
外科学 | 272篇 |
综合类 | 7篇 |
预防医学 | 252篇 |
眼科学 | 37篇 |
药学 | 218篇 |
中国医学 | 1篇 |
肿瘤学 | 371篇 |
出版年
2023年 | 29篇 |
2022年 | 58篇 |
2021年 | 110篇 |
2020年 | 73篇 |
2019年 | 92篇 |
2018年 | 122篇 |
2017年 | 87篇 |
2016年 | 80篇 |
2015年 | 108篇 |
2014年 | 140篇 |
2013年 | 144篇 |
2012年 | 285篇 |
2011年 | 286篇 |
2010年 | 149篇 |
2009年 | 150篇 |
2008年 | 225篇 |
2007年 | 224篇 |
2006年 | 193篇 |
2005年 | 194篇 |
2004年 | 173篇 |
2003年 | 151篇 |
2002年 | 121篇 |
2001年 | 34篇 |
2000年 | 21篇 |
1999年 | 22篇 |
1998年 | 24篇 |
1997年 | 12篇 |
1996年 | 9篇 |
1995年 | 8篇 |
1994年 | 7篇 |
1993年 | 8篇 |
1992年 | 9篇 |
1991年 | 11篇 |
1990年 | 8篇 |
1989年 | 9篇 |
1987年 | 9篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1979年 | 3篇 |
1977年 | 3篇 |
1976年 | 6篇 |
1975年 | 8篇 |
1974年 | 2篇 |
1972年 | 2篇 |
1971年 | 3篇 |
1970年 | 3篇 |
1965年 | 4篇 |
1938年 | 2篇 |
排序方式: 共有3455条查询结果,搜索用时 15 毫秒
81.
Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study 下载免费PDF全文
Florence Joly Remy Delva Loïc Mourey Emmanuel Sevin Emmanuelle Bompas Lionel Vedrine Alain Ravaud Jean‐Christophe Eymard Nicole Tubiana‐Mathieu Claude Linassier Nadine Houede Aline Guillot François Ringensen Oana Cojocarasu Bruno Valenza Alexandra Leconte Stéphanie Lheureux Bénédicte Clarisse Stéphane Oudard 《BJU international》2015,115(1):65-73
82.
Analysis of TCR,pT alpha,and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment 总被引:3,自引:4,他引:3
Asnafi V Beldjord K Boulanger E Comba B Le Tutour P Estienne MH Davi F Landman-Parker J Quartier P Buzyn A Delabesse E Valensi F Macintyre E 《Blood》2003,101(7):2693-2703
83.
Franck Rapaport Bertrand Boisson Anne Gregor Vivien Bziat Stphanie Boisson-Dupuis Jacinta Bustamante Emmanuelle Jouanguy Anne Puel Jrmie Rosain Qian Zhang Shen-Ying Zhang Joseph G. Gleeson Lluis Quintana-Murci Jean-Laurent Casanova Laurent Abel Etienne Patin 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(3)
Genetic variants underlying life-threatening diseases, being unlikely to be transmitted to the next generation, are gradually and selectively eliminated from the population through negative selection. We study the determinants of this evolutionary process in human genes underlying monogenic diseases by comparing various negative selection scores and an integrative approach, CoNeS, at 366 loci underlying inborn errors of immunity (IEI). We find that genes underlying autosomal dominant (AD) or X-linked IEI have stronger negative selection scores than those underlying autosomal recessive (AR) IEI, whose scores are not different from those of genes not known to be disease causing. Nevertheless, genes underlying AR IEI that are lethal before reproductive maturity with complete penetrance have stronger negative selection scores than other genes underlying AR IEI. We also show that genes underlying AD IEI by loss of function have stronger negative selection scores than genes underlying AD IEI by gain of function, while genes underlying AD IEI by haploinsufficiency are under stronger negative selection than other genes underlying AD IEI. These results are replicated in 1,140 genes underlying inborn errors of neurodevelopment. Finally, we propose a supervised classifier, SCoNeS, which predicts better than state-of-the-art approaches whether a gene is more likely to underlie an AD or AR disease. The clinical outcomes of monogenic inborn errors, together with their mode and mechanisms of inheritance, determine the levels of negative selection at their corresponding loci. Integrating scores of negative selection may facilitate the prioritization of candidate genes and variants in patients suspected to carry an inborn error.Negative (or purifying) selection is the natural process by which deleterious alleles are selectively purged from the population (1). In diploid species, the strength of negative selection at a given locus is predicted to increase with decreasing fitness and increasing dominance of the genetic variants controlling traits: Variation causing early death in the heterozygous state are the least likely to be transmitted to the next generation, as their carriers have fewer offspring than noncarriers (2). Human genetic variants that cause severe diseases are, thus, expected to be the primary targets of negative selection, particularly for diseases affecting heterozygous individuals. In humans, several studies have ranked protein-coding genes according to their levels of negative selection (3–5). Nevertheless, the extent to which negative selection affects human disease-causing genes, and the factors determining its strength, remain largely unknown, particularly because our knowledge of the severity, mode, and mechanism of inheritance of the corresponding human diseases remains incomplete (3, 6–8).The strength of negative selection at a given gene has been traditionally approximated by comparing the coding sequence of the gene in a given species with that of one or several closely related species; it depends on the proportion of amino acid changes that have accumulated during evolution (9–11). With the advent of high-throughput sequencing, intraspecies metrics have been developed, based on the comparison of the probability of predicted loss-of-function (pLOF) mutations for a gene under a random model with the frequency of pLOF mutations observed in population databases (5, 12, 13), which capture the species-specific evolution of genes. Using an interspecies-based method and a hand-curated version of the Online Mendelian Inheritance in Man (hOMIM) database, a previous study elegantly showed that most human genes for which mutations cause highly penetrant diseases, including autosomal dominant (AD) diseases in particular, evolve under stronger negative selection than genes associated with complex disorders (6). However, other studies based on OMIM genes have reported conflicting results (3, 14–17), probably due to the incompleteness and heterogeneity of the datasets used. Moreover, no study has yet addressed this problem with intraspecies metrics, even though it has been suggested that the choice of the reference species for interspecies metrics contributes to discrepancies across studies (6).We aimed to improve the identification of the drivers of negative selection acting on human disease-causing genes, by developing a negative selection score combining several informative intraspecies and interspecies statistics, focusing on inborn errors of immunity (IEI). IEI, previously known as primary immunodeficiencies (18), are genetic diseases that disrupt the development or function of human immunity. They form a large and expanding group of genetic diseases that has been widely studied, and they are well characterized physiologically (immunologically) and phenotypically (clinically) (19–21). IEI are often symptomatic in early childhood, and at least until the turn of the 20th century and the introduction of antibiotics, most individuals with IEI probably died before reaching reproductive maturity. Accordingly, IEI genes have probably been under strong negative selection from the dawn of humankind until very recently. In this study, we investigated whether the severity of IEI and their mode and mechanism of inheritance have left signatures of negative selection of various intensities in the corresponding human genes. Furthermore, we validated our model on genes underlying inborn errors of neurodevelopment (IEND), another group of well-characterized severe genetic diseases. 相似文献
84.
Thomas X Elhamri M Chelghoum Y Reman O Arnaud P Raffoux E Le QH Tavernier E Dombret H Michallet M 《Annals of hematology》2005,84(6):376-382
Following a dose-escalation study performed to assess the maximally tolerated dose of high-dose mitoxantrone in a single injection combined with chemotherapy, a phase II trial (EMA 2000 regimen) was performed in patients with refractory or relapsed acute myelogenous leukemia (AML) between October 2000 and December 2003. Sixty-two patients entered the study and received mitoxantrone 45 mg/m2 on day 1 in combination with cytarabine and etoposide. Overall, 39 patients (63%) achieved complete remission (CR). Four patients died during remission induction, and 19 patients had resistant disease. Median time to granulocyte and platelet recovery was 34 and 39 days, respectively. The predominant non-hematologic toxicity was infection, with 53% severe infections. Thirty-three of the 39 remitters received subsequent treatment consisting of maintenance chemotherapy courses in 17 patients, allogeneic stem cell transplantation (SCT) in 7 patients, and autologous SCT in 9 patients. The median overall survival of the entire cohort was 8.1 months, with 18% at 2.5 years. EMA chemotherapy using a single injection of mitoxantrone is effective in the treatment of high-risk AML. CR proportion was significantly higher in patients with a first CR duration 6 months when compared with those from a control trial using standard-dose mitoxantrone (90 vs 70%, p=0.03). 相似文献
85.
Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure. 总被引:9,自引:0,他引:9
Guillaume Lecoq Christophe Leclercq Emmanuelle Leray Christophe Crocq Christine Alonso Christian de Place Philippe Mabo Claude Daubert 《European heart journal》2005,26(11):1094-1100
AIMS: Cardiac resynchronization therapy (CRT) is an effective treatment for refractory congestive heart failure (CHF). However, up to 30% of patients do not respond to CRT. The aim of this study was to identify clinical and electrocardiographic (ECG) predictors of a positive response to CRT. METHODS AND RESULTS: This retrospective study included 139 consecutive patients successfully implanted with a CRT device (mean age, 68+/-9 years, 113 men). At baseline, 69% of patients were in New York Heart Association (NYHA) functional class III, and 31% in class IV, mean left ventricular ejection fraction was 21+/-6%, and mean QRS duration was 188+/-28 ms. In each patient, left and right ventricular leads were placed to attain the shortest QRS duration during biventricular stimulation. Patients were classified at 6 months as responders to CRT (n=100) if they were alive, they had not been re-hospitalized for management of CHF, and the NYHA class had decreased by 1 point, and/or peak VO(2) or 6 min hall-walk increased by >10%. All others were classified as non-responders (n=38; one patient was lost to follow-up). Uni- and multivariate logistic regression analyses were performed to detect a pre- or intra-operative predictor of a positive response to CRT. Among multiple demographic, clinical, and ECG variables, the amount of QRS shortening (DeltaQRS) associated with biventricular stimulation was the only independent predictor of a positive (37+/-23 ms) vs. negative (11+/-23 ms) response to CRT (P<0.001). CONCLUSION: A positive response to CRT was observed in 73% of patients at 6 months and predicted only by DeltaQRS. 相似文献
86.
87.
Emmanuelle Orset Philippe Chaffanjon Georges Bettega 《Surgical and radiologic anatomy : SRA》2014,36(2):163-166
Purpose
The temporomandibular joint (TMJ) is a complex anatomic structure with various pathologies as fractures, ankylosis or degenerative diseases. Few animal models already exist and the current study aims at demonstrating that rats’ TMJ could be considered as a model, using anatomic dissection and radiology.Methods
Five adult Wistar rats were dissected to explore the soft and bone anatomy of the TMJ. Five more adult Wistar rats underwent a CT scan to measure size and angles of the condyle.Results
The angles between the condyle and the mandible corpus were observed to be different both in the sagittal plane (150° vs. 125° in human) and the transversal plane (140° vs. 180°). The condyle axis is sagittal and drop-shaped and there is no anterior eminence in rats’ temporal fossa. However, the other anatomic structures proved to be quite similar.Conclusions
The temporomandibular joints in human and rat are close and only few anatomic differences have been reported. Rats thus appear as an interesting and cheap alternative to model TMJ. 相似文献88.
André Maues De Paula Alexandre Vasiljevic Roch Giorgi Anne Gomez-Brouchet Sébastien Aubert Xavier Leroy Hélène Duval Gonzague de Pinieux Corinne Bouvier 《Virchows Archiv : an international journal of pathology》2014,465(4):487-494
Some primary malignant or benign tumours of bone contain numerous multinucleated cells. These “giant cell-rich tumours of bone” have overlapping features and clinical and radiological data are needed to reach an accurate pathological diagnosis. We studied the potential contribution of p63 immunohistochemistry to the reliability of the histological diagnosis. We performed a multicentric retrospective study of 291 giant cell-rich tumours of bone which included 119 giant cell tumours of bone (GCTB), 76 aneurysmal bone cysts (ABC), 49 chondroblastomas (CB), 15 nonossifying fibromas (NOF), 10 giant cell reparative granulomas (RG) of jaws, 1 giant cell lesion of small bones, 2 hyperparathyroidism-related brown tumours (BT), 17 bone sarcomas with numerous osteoclasts and 2 malignant giant cell tumours of bone. p63 is expressed in ABC, CB, NOF, RG, BT and GCTB, but its expression in more than 50 % of mononuclear cells is strongly suggestive of a diagnosis of GCTB. In contrast, malignant GCTB were mostly negative. Our results show that p63 is expressed in a broad range of benign giant cell-rich tumours of bone, consistent with data in the recent literature, while infrequent in malignant tumours. With a cut-off 50 %, the presence of p63 positive cells is useful in supporting a diagnosis of giant cell-rich tumour of bone. However, a final diagnosis cannot be made without due consideration of all clinical/radiological and pathological data. 相似文献
89.
W. A. Carrock Sewell Jacqueline Kerr Marie‐Emmanuelle Behr‐Gross Hans‐Hartmut Peter 《European journal of immunology》2014,44(8):2207-2214
The use of immunoglobulin (Ig) preparations (intravenous, IVIg, subcutaneous, SCIg) for replacement and immunomodulation therapy worldwide has tripled in the past 20 years and represents an ever‐increasing cost factor for healthcare organizations. The limited access to the starting material of this essential medicinal product is currently the driving force for human plasma collection. Increasing awareness and improved diagnosis of human primary immunodeficiencies and a broadening of immunomodulatory indications are responsible for this development, and on a longer run might lead to plasma supply shortages. Consensus recommendations for the optimal use of Ig in clinical practice, including priority rankings for the most urgent indications, are therefore urgently needed. During a recent meeting in Kreuth, Germany, expert nominees from 36 Council of Europe states, together with colleagues from observer countries and regulatory agencies came up with this consensus statement.
90.
Alexandre Marchand Jean‐Antoine Martin David Collot Olivier Hoang Ingrid Roulland Florian Semence Pierre‐Edouard Sottas Michel Audran Emmanuelle Varlet‐Marie 《Drug testing and analysis》2019,11(11-12):1698-1713
The combination of growth hormone (GH) and recombinant erythropoietin (rEPO) is thought to be used particularly in endurance sports. Our objective was to reproduce a 2‐week administration of rEPO microdoses alone or in combination with GH microdoses (three times a week) on healthy and athletic male subjects and to evaluate if GH had any additional effects compared to EPO treatment alone. The effects of the treatments on hematological parameters and VO2max were studied as well as the detection of GH in serum. While the rEPO microdose regimen was associated with a significant increase in reticulocytes, no clear elevation in hemoglobin concentration (HGB) was observed. Using a correction by plasma volume did not reveal more effects of EPO on HGB. Our results did not show any additional effect when the GH microdoses were co‐administered. In addition, no clear increase in VO2max was observed after treatment, with an elevation in only half the subjects in both groups (EPO and EPO+GH). A clear effect of GH on insulin‐like growth factor I (IGF‐I) was seen but it was lower on procollagen III amino‐terminal propeptide (P‐III‐NP). GH detection using the direct isoform test identified only one subject 24 hours after receiving GH. The GH biomarker test combining IGF‐I and P‐III‐NP was not able to detect the GH administration. However, a longitudinal follow‐up of the intraindividual variations showed a significant increase in IGF‐I 24 and 48 hours after GH administration in most subjects, while the effect of GH microdoses on P‐III‐NP was less straightforward. 相似文献